Skip to main content
bioRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search
New Results

NmeCas9 is an intrinsically high-fidelity genome editing platform

Nadia Amrani, Xin D. Gao, Pengpeng Liu, Ankit Gupta, Alireza Edraki, Raed Ibraheim, Kanae E. Sasaki, View ORCID ProfileLihua Julie Zhu, Scot A. Wolfe, View ORCID ProfileErik J. Sontheimer
doi: https://doi.org/10.1101/172650
Nadia Amrani
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xin D. Gao
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pengpeng Liu
3Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
4Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ankit Gupta
3Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alireza Edraki
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Raed Ibraheim
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kanae E. Sasaki
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lihua Julie Zhu
2Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
3Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
5Program in Bioinformatics and Integrative Biology, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Lihua Julie Zhu
Scot A. Wolfe
3Department of Molecular, Cell and Cancer Biology, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
4Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erik J. Sontheimer
1RNA Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
2Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, U.S.A.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Erik J. Sontheimer
  • For correspondence: erik.sontheimer@umassmed.edu
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Preview PDF
Loading

ABSTRACT

The development of CRISPR-Cas9 RNA-guided genome editing has transformed biomedical research. Most applications reported thus far rely upon the Cas9 protein from Streptococcus pyogenes SF370 (SpyCas9). With many RNA guides, SpyCas9 can induce significant levels of unintended mutations at near-cognate sites, necessitating substantial efforts toward the development of strategies to minimize off-target activity. Although the genome-editing potential of thousands of other Cas9 orthologs remains largely untapped, it is not known how many will require similarly extensive engineering efforts to achieve single-site accuracy within large (e.g. mammalian) genomes. In addition to its off-targeting propensity, SpyCas9 is encoded by a relatively large (∼4.2 kb) open reading frame (ORF), limiting its utility in applications that require size-restricted delivery strategies such as adeno-associated virus (AAV) vectors. In contrast, some genome-editing-validated Cas9 orthologs [e.g. Staphylococcus aureus Cas9 (SauCas9), Campylobacter jejuni Cas9 (CjeCas9), and Neisseria meningitidis Cas9 (NmeCas9)] are considerably smaller and therefore better suited for viral delivery. Here we show that wild-type NmeCas9, when programmed with guide sequences of natural length (24 nucleotides), exhibits a nearly complete absence of unintended targeting in human cells, even when targeting sites that are highly prone to off-target activity when employing SpyCas9. We also validate at least six variant protospacer adjacent motifs (PAMs), in addition to the preferred consensus PAM (5’-N4GATT-3’), for NmeCas9 genome editing in human cells. Our results show that NmeCas9 is a naturally high-fidelity genome editing enzyme, and suggest that additional Cas9 orthologs may prove to exhibit similarly high accuracy, even without extensive engineering efforts.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted August 04, 2017.
Download PDF

Supplementary Material

Email

Thank you for your interest in spreading the word about bioRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
NmeCas9 is an intrinsically high-fidelity genome editing platform
(Your Name) has forwarded a page to you from bioRxiv
(Your Name) thought you would like to see this page from the bioRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
NmeCas9 is an intrinsically high-fidelity genome editing platform
Nadia Amrani, Xin D. Gao, Pengpeng Liu, Ankit Gupta, Alireza Edraki, Raed Ibraheim, Kanae E. Sasaki, Lihua Julie Zhu, Scot A. Wolfe, Erik J. Sontheimer
bioRxiv 172650; doi: https://doi.org/10.1101/172650
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
NmeCas9 is an intrinsically high-fidelity genome editing platform
Nadia Amrani, Xin D. Gao, Pengpeng Liu, Ankit Gupta, Alireza Edraki, Raed Ibraheim, Kanae E. Sasaki, Lihua Julie Zhu, Scot A. Wolfe, Erik J. Sontheimer
bioRxiv 172650; doi: https://doi.org/10.1101/172650

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Molecular Biology
Subject Areas
All Articles
  • Animal Behavior and Cognition (4234)
  • Biochemistry (9128)
  • Bioengineering (6778)
  • Bioinformatics (23998)
  • Biophysics (12119)
  • Cancer Biology (9527)
  • Cell Biology (13776)
  • Clinical Trials (138)
  • Developmental Biology (7633)
  • Ecology (11693)
  • Epidemiology (2066)
  • Evolutionary Biology (15506)
  • Genetics (10640)
  • Genomics (14322)
  • Immunology (9479)
  • Microbiology (22832)
  • Molecular Biology (9089)
  • Neuroscience (48987)
  • Paleontology (355)
  • Pathology (1481)
  • Pharmacology and Toxicology (2569)
  • Physiology (3844)
  • Plant Biology (8328)
  • Scientific Communication and Education (1471)
  • Synthetic Biology (2296)
  • Systems Biology (6188)
  • Zoology (1300)